Summary of Study ST003106

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001775. The data can be accessed directly via it's Project DOI: http://dx.doi.org/10.21228/M88M6V This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST003106
Study Title13C-palmitate labeling experiment in ICC13-7 treated with DMSO or Infigratinib
Study SummaryGenomic alterations that activate FGFR2 are common in intrahepatic cholangiocarcinoma (ICC) and confer sensitivity to treatment with FGFR inhibitors. However, the depth and duration of responses are often limited. Here, we conducted integrative transcriptomic and metabolomic analysis of patient-derived models to define the pathways that fuel tumor growth downstream of oncogenic FGFR2 signaling in ICC and to uncover compensatory mechanisms associated with pathway inhibition. We find FGFR2-mediated activation of NF-B maintains a highly glycolytic phenotype. Conversely, FGFR inhibition blocks glucose uptake and glycolysis while inciting a series of adaptive changes, including switching fuel source utilization to favor fatty acid oxidation and increasing mitochondrial fusion and autophagy. Accordingly, FGFR inhibitor efficacy is potentiated by combined mitochondrial targeting, an effect enhanced in xenograft models by intermittent fasting. Thus, we show that oncogenic FGFR2 signaling drives NF-kB-dependent glycolysis in ICC and that metabolic reprogramming in response to FGFR inhibition confers new targetable vulnerabilities.
Institute
Massachusetts General Hospital
Last NameZhen
First NameYuanli
Address185 cambridge street, room 4100
Emailyzhen1@mgh.harvard.edu
Phone4698792279
Submit Date2024-01-17
Raw Data AvailableYes
Raw Data File Type(s)raw(Thermo)
Analysis Type DetailLC-MS
Release Date2024-03-20
Release Version1
Yuanli Zhen Yuanli Zhen
http://dx.doi.org/10.21228/M88M6V
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:


Factors:

Subject type: Cultured cells; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Treatment Sample source
SA333652SUB13607p4_SPL07DMSO ICC13-7 cells
SA333653SUB13607p4_SPL09DMSO ICC13-7 cells
SA333654SUB13607p4_SPL08DMSO ICC13-7 cells
SA333655SUB13607p4_SPL12Infigratinib ICC13-7 cells
SA333656SUB13607p4_SPL10Infigratinib ICC13-7 cells
SA333657SUB13607p4_SPL11Infigratinib ICC13-7 cells
Showing results 1 to 6 of 6
  logo